Current Insights in the Development of Efficacious Vaccines Against RSV

Current Insights in the Development of Efficacious Vaccines Against RSV

Bibliographic Details
Main Authors:	Jorge A. Soto, Laura M. Stephens, Kody A. Waldstein, Gisela Canedo-Marroquín, Steven M. Varga, Alexis M. Kalergis
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-07-01
Series:	Frontiers in Immunology
Subjects:	Respiratory Syncytial Virus treatments vaccines antibodies T cells
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2020.01507/full

Similar Items

Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population
by: Laura M. Stephens, et al.
Published: (2021-06-01)

Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines
by: Xanthippi Topalidou, et al.
Published: (2023-10-01)

Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection
by: Karen Bohmwald, et al.
Published: (2019-03-01)

Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody
by: Bryony Treston, et al.
Published: (2024-12-01)

Polish expert group recommendations for RSV vaccination in adults
by: Aneta Nitsch-Osuch, et al.
Published: (2024-09-01)

Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development
by: Pius I. Babawale, et al.
Published: (2025-01-01)

Function and Modulation of Type I Interferons during Respiratory Syncytial Virus Infection
by: Laura M. Stephens, et al.
Published: (2020-04-01)

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)
by: Dvir Gatt, et al.
Published: (2023-01-01)

New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus
by: Diethelm-Varela B, et al.
Published: (2023-04-01)

Induction of Trained Immunity by Recombinant Vaccines
by: Camila Covián, et al.
Published: (2021-01-01)

The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV
by: Lori M. Cullen, et al.
Published: (2017-12-01)

Current Animal Models for Understanding the Pathology Caused by the Respiratory Syncytial Virus
by: María José Altamirano-Lagos, et al.
Published: (2019-05-01)

Perceptions about respiratory syncytial virus (RSV) and attitudes toward the RSV vaccine among the general public in China: A cross-sectional survey
by: Qiang Wang, et al.
Published: (2024-12-01)

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization
by: Sarah Wilmschen, et al.
Published: (2019-07-01)

Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies
by: Harrison C. Bergeron, et al.
Published: (2021-02-01)

Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures
by: Charles Nuttens, et al.
Published: (2024-07-01)

The CD8 T Cell Response to Respiratory Virus Infections
by: Megan E. Schmidt, et al.
Published: (2018-04-01)

Functional Impairment of Mononuclear Phagocyte System by the Human Respiratory Syncytial Virus
by: Karen Bohmwald, et al.
Published: (2017-11-01)

Maternal RSV vaccine development. Where to from here?
by: Ahinsa Gunatilaka, et al.
Published: (2021-11-01)

Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
by: Johan L. Van Der Plas, et al.
Published: (2020-06-01)

Contribution of Resident Memory CD8<sup>+</sup> T Cells to Protective Immunity against Respiratory Syncytial Virus and Their Impact on Vaccine Design
by: Angello Retamal-Díaz, et al.
Published: (2019-09-01)

Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis
by: David Hodgson, et al.
Published: (2020-11-01)

Global molecular diversity of RSV – the “INFORM RSV” study
by: Annefleur C. Langedijk, et al.
Published: (2020-06-01)

Current GMP standards for the production of vaccines and antibodies: An overview
by: Consuelo E. Covarrubias, et al.
Published: (2022-11-01)

Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age
by: Georgios Papazisis, et al.
Published: (2024-03-01)

Recombinant BCG Vaccines Reduce Pneumovirus-Caused Airway Pathology by Inducing Protective Humoral Immunity
by: Jorge A. Soto, et al.
Published: (2018-12-01)

Maternal Vaccination for the Prevention of Infantile RSV Disease: An Overview of the Authorized, In-Progress, and Rejected Vaccine Candidates
by: Georgios Papazisis, et al.
Published: (2024-08-01)

Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults
by: Adriana Weinberg, et al.
Published: (2019-10-01)

Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients
by: Xunyan Ye, et al.
Published: (2021-05-01)

Potential Neurocognitive Symptoms Due to Respiratory Syncytial Virus Infection
by: Catalina A. Andrade, et al.
Published: (2021-12-01)

Induction of Protective Immunity by a Single Low Dose of a Master Cell Bank cGMP-rBCG-P Vaccine Against the Human Metapneumovirus in Mice
by: Jorge A. Soto, et al.
Published: (2021-06-01)

A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States
by: Martine C. Maculaitis, et al.
Published: (2024-12-01)

Respiratory Syncytial Virus (RSV) and Intention to Recommend RSV Vaccination: A Cross-Sectional Survey of Cardiologists and Cardiac Nurses in Southern Italy
by: Domenico Ponticelli, et al.
Published: (2024-02-01)

Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein
by: Lori M. Cullen, et al.
Published: (2019-02-01)

Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
by: Alexander Domnich, et al.
Published: (2025-01-01)

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life
by: Tessa Hosman, et al.
Published: (2024-12-01)

The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study
by: José Francisco Barbas Del Buey, et al.
Published: (2024-08-01)

Serological Survey Of Respiratory Syncytial Virus (RSV) Among Children In Lorin North-Central, Nigeria.
by: Odebisi- Omokanye, et al.
Published: (2018-02-01)

Maternal awareness, acceptability and willingness towards respiratory syncytial virus (RSV) vaccination during pregnancy in Ireland
by: Siobhan McCormack, et al.
Published: (2024-04-01)

Immunoinformatics-Aided Analysis of RSV Fusion and Attachment Glycoproteins to Design a Potent Multi-Epitope Vaccine
by: Hamza Arshad Dar, et al.
Published: (2022-08-01)